Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical validation of anti‐nuclear factor‐kappa B therapy to inhibit human vestibular schwannoma growth

31 Mar 2015

Abstract excerpt

Vestibular schwannomas (VSs), the most common tumors of the cerebellopontine angle, arise from Schwann cells lining the vestibular nerve. Pharmacotherapies against VS are almost non-existent. Although the therapeutic inhibition of inflammatory modulators has been established for other neoplasms, it has not been explored in VS. A bioinformatic network analysis of all genes reported to be differentially expressed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ear and Head Tumors
Share to Neurofibromatosis and Schwannoma Cases
Share to Silk-based biomaterials and applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25891780
DOI: 10.1016/j.molonc.2015.03.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical validation of anti‐nuclear factor‐kappa B therapy to inhibit human vestibular schwannoma growthPMID 25891780Read ↗

Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannomaSemantic proximity Read ↗

Exploring the Role of Inflammatory Genes and Immune Infiltration in Vestibular Schwannomas PathogenesisSemantic proximity Read ↗

Direct and abscopal anti-tumor responses elicited by peripheral nerve schwannoma irradiation synergize with anti-PD1 treatment in vestibular schwannoma modelsSemantic proximity Read ↗

Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas.Semantic proximity Read ↗

Single-cell transcriptomes reveal the heterogeneity and microenvironment of vestibular schwannomaSemantic proximity Read ↗

Identification of Potential Core Genes and Potential Drugs in Vestibular SchwannomaSemantic proximity Read ↗

Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.Semantic proximity Read ↗

Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future DirectionsSemantic proximity Read ↗

CPI-17 Overexpression and Its Correlation With the NF2 Mutation Spectrum in Sporadic Vestibular Schwannomas.Semantic proximity Read ↗

Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas.Semantic proximity Read ↗

Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cellsSemantic proximity Read ↗

Novel patient‐derived xenograft and cell line models for therapeutic screening in NF2 ‐associated schwannomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.